Teligent Inc (NEW JERSEY)
OTC:TLGTQ
Intrinsic Value
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of TLGTQ.
Fundamental Analysis
Balance Sheet Decomposition
Teligent Inc (NEW JERSEY)
| Current Assets | 51.5m |
| Cash & Short-Term Investments | 22.6m |
| Receivables | 9.8m |
| Other Current Assets | 19m |
| Non-Current Assets | 38.9m |
| PP&E | 17.8m |
| Intangibles | 19.7m |
| Other Non-Current Assets | 1.5m |
| Current Liabilities | 12.6m |
| Accounts Payable | 4m |
| Accrued Liabilities | 8m |
| Other Current Liabilities | 582k |
| Non-Current Liabilities | 121.4m |
| Long-Term Debt | 116.5m |
| Other Non-Current Liabilities | 4.8m |
Earnings Waterfall
Teligent Inc (NEW JERSEY)
|
Revenue
|
46.3m
USD
|
|
Cost of Revenue
|
-55.3m
USD
|
|
Gross Profit
|
-9m
USD
|
|
Operating Expenses
|
-35m
USD
|
|
Operating Income
|
-44m
USD
|
|
Other Expenses
|
-47.6m
USD
|
|
Net Income
|
-91.6m
USD
|
Free Cash Flow Analysis
Teligent Inc (NEW JERSEY)
TLGTQ Profitability Score
Profitability Due Diligence
Teligent Inc (NEW JERSEY)'s profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Teligent Inc (NEW JERSEY)'s profitability score is 36/100. The higher the profitability score, the more profitable the company is.
TLGTQ Solvency Score
Solvency Due Diligence
Teligent Inc (NEW JERSEY)'s solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Teligent Inc (NEW JERSEY)'s solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLGTQ Price Targets Summary
Teligent Inc (NEW JERSEY)
Shareholder Return
TLGTQ Price
Teligent Inc (NEW JERSEY)
| Average Annual Return |
N/A
|
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -100% |
| Market Capitalization | 18.6k USD |
| Shares Outstanding | 92 817 504 |
| Percentage of Shares Shorted | 2.48% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. The company is headquartered in Buena, New Jersey and currently employs 142 full-time employees. The company went IPO on 2020-10-27. The firm is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. The company also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The firm's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).
You don't have any saved screeners yet
